5 Key Takeaways

• 1

  Two phase III trials showed that roflumilast cream, 0.15%, may improve atopic dermatitis symptoms within 4 weeks.

• 2

  The trials involved 1,337 participants aged 6 years and older, with a primary endpoint of achieving vIGA-AD success at week 4.

• 3

  In INTEGUMENT-1, 32.0% of roflumilast patients achieved vIGA-AD success compared to 15.2% in the vehicle group (P < .001).

• 4

  In INTEGUMENT-2, 28.9% of roflumilast patients met the vIGA-AD endpoint versus 12.0% in the vehicle group (P < .001).

• 5

  Roflumilast was well tolerated, with over 95% of participants showing no irritation at the application site.